Get the Stockscreener App
719.51
0.93%
6.65
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Mckesson Corporation stock is traded at $719.51, with a volume of 1.33M.
It is up +0.93% in the last 24 hours and up +1.73% over the past month.
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
See More
Previous Close:
$712.86
Open:
$712.18
24h Volume:
1.33M
Relative Volume:
1.31
Market Cap:
$90.02B
Revenue:
$359.05B
Net Income/Loss:
$3.30B
P/E Ratio:
27.86
EPS:
25.83
Net Cash Flow:
$5.23B
1W Performance:
+0.48%
1M Performance:
+1.73%
6M Performance:
+14.48%
1Y Performance:
+28.26%
1-Day Range:
$710.50
$724.26
1-Week Range:
$704.99
$724.26
52-Week Range:
$464.42
$731.00
Mckesson Corporation Stock (MCK) Company Profile
Name
Mckesson Corporation
Sector
Industry
Phone
972-446-4800
Address
6555 STATE HIGHWAY 161, IRVING, TX
Compare MCK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCK
Mckesson Corporation
|
719.51 | 89.51B | 359.05B | 3.30B | 5.23B | 25.83 |
|
COR
Cencora Inc
|
291.24 | 56.66B | 310.23B | 1.69B | 3.58B | 8.62 |
|
CAH
Cardinal Health Inc
|
154.44 | 36.46B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
69.99 | 8.96B | 12.50B | 314.00M | 421.00M | 2.44 |
|
YI
111 Inc Adr
|
8.17 | 68.73M | 2.05B | -45.99M | 5.54M | -0.5634 |
Mckesson Corporation Stock (MCK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Resumed | Mizuho | Neutral |
| Nov-07-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-05-24 | Reiterated | Leerink Partners | Outperform |
| Aug-08-24 | Reiterated | Mizuho | Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| Jul-06-22 | Downgrade | Argus | Buy → Hold |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-02-21 | Reiterated | Barclays | Overweight |
| Nov-02-21 | Reiterated | BofA Securities | Buy |
| Nov-02-21 | Reiterated | Evercore ISI | Outperform |
| Nov-02-21 | Reiterated | Jefferies | Buy |
| Mar-30-21 | Upgrade | Argus | Hold → Buy |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-04-20 | Upgrade | Deutsche Bank | Hold → Buy |
| May-22-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-18-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-13-20 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-10-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-05-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jul-22-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Oct-26-18 | Reiterated | Barclays | Equal Weight |
| Jul-20-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-29-18 | Reiterated | Leerink Partners | Mkt Perform |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-02-18 | Reiterated | Mizuho | Neutral |
| Jan-24-18 | Upgrade | Jefferies | Hold → Buy |
View All
Mckesson Corporation Stock (MCK) Latest News
McKesson Issues $2 Billion Notes for Acquisition - MSN
Insider Sell: Leann Smith Sells Shares of McKesson Corp (MCK) - GuruFocus
Insider Sell: Thomas Rodgers Sells Shares of McKesson Corp (MCK) - GuruFocus
McKesson EVP LeAnn B. Smith sells $244,807 in stock By Investing.com - Investing.com South Africa
McKesson CFO Vitalone sells $1.35 million in common stock - Investing.com Australia
McKesson CFO Vitalone sells $1.35 million in common stock By Investing.com - Investing.com India
McKesson’s EVP Thomas Rodgers sells $366,134 in stock By Investing.com - Investing.com India
McKesson’s EVP Thomas Rodgers sells $366,134 in stock - Investing.com
McKesson EVP LeAnn B. Smith sells $244,807 in stock - Investing.com India
McKesson corp executive sells $68,201 in stock - Investing.com
Ex-Dividend Reminder: Clearway Energy, NextEra Energy and McKesson - Nasdaq
Why McKesson (MCK) is a Top Value Stock for the Long-Term - Yahoo Finance
Nephron Research Adjusts McKesson Price Target to $780 From $750 - marketscreener.com
Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock - sharewise
Here's Why McKesson (MCK) is a Strong Momentum Stock - Yahoo Finance
Here's How Much You Would Have Made Owning McKesson Stock In The Last 15 Years - Benzinga
McKesson’s chief HR officer LeAnn Smith sells shares worth $895,190 By Investing.com - Investing.com Nigeria
McKesson’s chief HR officer LeAnn Smith sells shares worth $895,190 - Investing.com India
McKesson Stock: Is Wall Street Bullish or Bearish? - MSN
McKesson Stock: Is Wall Street Bullish Or Bearish? - Barchart.com
Is McKesson (MCK) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
McKesson’s SVP Rutledge Napoleon sells $394,494 in stock - Investing.com
McKesson’s SVP Rutledge Napoleon sells $394,494 in stock By Investing.com - Investing.com India
McKesson stock soars to all-time high of $728.49 amid robust growth - Investing.com Nigeria
McKesson Corp Files For Three-Part Notes Offering Size Not DisclosedSEC Filing - marketscreener.com
Jim Cramer Notes McKesson (MCK) Reported “Very Strong Set of Numbers” - Insider Monkey
McKesson: Sustained Rally Backed By Strong Financials - Seeking Alpha
Why McKesson Stock Bumped Modestly Higher Today - MSN
McKesson Full Year 2025 Earnings: EPS Beats Expectations - simplywall.st
McKesson To Spin-Off Its Medical-Surgical Solutions Business - Forbes
3 Reasons Growth Investors Will Love McKesson (MCK) - Yahoo Finance
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
McKesson at Bank of America Conference: Strategic Growth and Separation By Investing.com - Investing.com India
McKesson at Bank of America Conference: Strategic Growth and Separation - Investing.com
Transcript : McKesson Corporation Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Here's What Key Metrics Tell Us About McKesson (MCK) Q4 Earnings - MSN
Here's How Much $100 Invested In McKesson 15 Years Ago Would Be Worth Today - Benzinga
TD Cowen Raises Price Target for McKesson (MCK) to $820 | MCK St - GuruFocus
McKesson projects $36.75-$37.55 EPS for fiscal 2026 with oncology and biopharma growth - MSN
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Here’s Why Baron Health Care Fund Reacquired McKesson Corporation (MCK) in Q1 - Insider Monkey
TD Cowen Adjusts Price Target on McKesson to $820 From $695, Maintains Buy Rating - marketscreener.com
McKesson stock up on encouraging 2026 profit guidance - MSN
Mckesson Corporation Stock (MCK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
2.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):